NEW YORK, Aug. 8, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2017.
Highlights from the second quarter of 2017 and recent weeks include:
